stem
cell
transplant
sct
accept
treatment
certain
hematolog
nonhematolog
cancer
howev
infecti
noninfecti
pulmonari
complic
report
occur
sct
infecti
pulmonari
complic
major
caus
morbid
death
sct
howev
clinic
present
radiolog
appear
noninfecti
drug
radiat
toxic
bronchiol
obliteran
pulmonari
diseas
diffus
alveolar
damag
pulmonari
hemorrhag
pulmonari
edema
cardiogen
noncardiogen
acut
respiratori
distress
syndrom
idiopath
noninfecti
pulmonari
mimic
infecti
microbiolog
diagnosi
infecti
pulmonari
complic
often
requir
comput
tomographi
ct
fiberopt
bronchoscopi
fob
bronchoalveolar
lavag
bal
fob
bal
gener
consid
safe
valuabl
procedur
evalu
pulmonari
complic
sct
recipi
undergo
infecti
pulmonari
bal
specimen
evalu
array
diagnost
microbiolog
studi
target
variou
pathogen
includ
bacteria
mycobacteria
fungi
virus
prior
publish
studi
report
diagnost
yield
bal
rang
data
often
combin
diagnost
yield
infecti
noninfecti
pulmonari
complic
sct
recipi
report
focu
exclus
microbiolog
yield
bal
sct
recipi
therefor
sought
determin
elabor
overal
microbiolog
yield
bal
recipi
autolog
allogen
sct
underw
infecti
pulmonari
institut
studi
cohort
consist
sct
recipi
underw
bal
procedur
januari
juli
institut
part
infecti
fever
respiratori
symptom
new
pulmonari
radiograph
abnorm
patient
multipl
bronchoscopi
procedur
encount
consid
independ
procedur
patient
receiv
count
toward
allogen
dataset
ich
bal
order
set
institut
studi
period
consist
follow
test
bacteri
gram
stain
cultur
fungal
smear
cultur
bacilli
smear
cultur
aspergillu
antigen
aspag
coccidioid
speci
cocci
polymeras
chain
reaction
pcr
legionella
speci
cultur
pcr
pneumocysti
jirovecii
smear
pcr
cytomegaloviru
cultur
herp
simplex
viru
cultur
varicella
cultur
viru
ebv
pcr
viral
respiratori
cultur
cytolog
evalu
bal
aspag
test
incorpor
ich
bal
panel
may
follow
data
collect
bal
age
gender
date
type
indic
sct
date
fob
bal
presenc
diseas
time
bal
neutropenia
defin
absolut
neutrophil
count
hour
bal
corticosteroid
use
specif
empir
antimicrobi
therapi
least
hour
bal
radiograph
find
chest
ct
chest
radiograph
sputum
cultur
serum
cytomegaloviru
pcr
staphylococcu
aureu
mrsa
nasal
swab
ns
nasopharyng
np
influenza
pcr
legionella
urinari
antigen
within
day
bal
serum
cocci
serolog
test
serum
aspag
day
week
bal
addit
detail
inform
regard
ich
bal
test
result
collect
patient
chest
ct
chest
radiograph
find
group
categori
diffus
focal
consolid
opac
ggo
nodul
solid
ground
glass
cavit
bronchial
impact
categori
mutual
exclus
diffus
defin
bilater
involv
abnorm
extend
beyond
lobe
empir
antimicrobi
therapi
administ
within
hour
collect
bal
specimen
record
prophylact
antimicrobi
regimen
includ
analysi
empir
antimicrobi
therapi
defin
antibacteri
therapi
candida
staphylococcu
ebv
exclud
microbiolog
yield
analysi
pathogen
group
primari
categori
bacteria
fungi
virus
mix
data
analyz
determin
elabor
microbiolog
yield
bal
sct
recipi
ii
assess
correl
bal
studi
less
invas
mean
pathogen
detect
iii
evalu
util
repeat
bal
within
day
mayo
clinic
institut
review
board
approv
studi
among
patient
underw
bal
receiv
empir
antimicrobi
therapi
take
antibacteri
antifung
antivir
therapi
respect
tabl
mrsa
isol
bal
cultur
obtain
patient
four
concord
mrsa
sputum
cultur
two
bal
posit
mrsa
cultur
receiv
therapi
eighti
case
mrsa
ns
test
one
mrsa
ns
found
posit
also
concord
posit
mrsa
bal
cultur
neg
mrsa
nss
concord
neg
bal
specimen
test
perform
neg
sputum
cultur
well
neg
predict
valu
posit
mrsa
bal
cultur
addit
posit
mrsa
sputum
cultur
ns
test
case
involv
chest
ct
find
diffus
consolid
patient
cavit
fourteen
bal
cultur
reveal
collect
recipi
one
concurr
sputum
cultur
pseudomona
case
antipseudomon
antimicrobi
therapi
administ
bal
collect
case
appropri
therapi
base
suscept
test
period
antipseudomon
therapi
bal
rang
day
median
interquartil
rang
day
thirteen
case
chest
ct
bal
collect
common
ct
find
consolid
follow
ggo
seven
diffus
abnorm
two
case
show
cavitari
lesion
case
also
concurr
detect
aspergillu
legionella
isol
bal
retriev
concurr
posit
bal
legionella
pcr
two
case
diagnos
within
day
one
day
admiss
requir
intens
care
unit
admiss
day
later
case
separ
time
least
month
two
case
receiv
therapi
within
hour
bal
collect
legionella
urinari
antigen
obtain
case
posit
legionella
pneumophilia
serogroup
unspecifi
l
pneumophilia
group
case
neg
urinari
antigen
test
involv
bal
cultur
show
legionella
bozemanii
four
case
chest
ct
common
radiograph
abnorm
observ
dens
lobar
segment
consolid
twenti
bal
posit
aspergillu
patient
three
differ
method
use
assess
presenc
aspergillu
bal
cultur
bal
aspag
serum
aspag
tabl
list
frequenc
test
concord
number
bal
fungal
cultur
bal
aspag
serum
aspag
test
respect
posit
result
note
sampl
bal
cultur
bal
aspag
serum
aspag
respect
concord
seen
among
test
posit
bal
cultur
serum
aspag
bal
aspergillu
identifi
bal
aspag
bal
fungal
cultur
patient
receiv
therapi
take
therapi
longer
day
bal
collect
addit
aspergillu
found
bal
along
anoth
pathogen
patient
bal
posit
aspergillu
result
chest
ct
common
radiograph
featur
ggo
area
consolid
three
case
found
show
cavitari
lesion
chest
ct
identifi
bal
aspag
posit
bal
cultur
eight
posit
result
detect
bal
p
jirovecii
detect
patient
case
bal
p
jirovecii
fluoresc
smear
test
test
posit
corticosteroid
therapi
given
case
case
receiv
p
jirovecii
prophylaxi
pentamidin
common
ct
find
among
case
diffus
ggo
coccidioid
speci
detect
bal
fungal
smear
cultur
pcr
posit
cocci
result
bal
pcr
concurr
posit
bal
cultur
neg
serum
cocci
serolog
posit
bal
cocci
pcr
patient
serum
cocci
serolog
test
case
posit
cocci
serolog
result
concord
bal
pcr
common
radiograph
find
chest
ct
consolid
ggo
common
virus
detect
ebv
follow
parainfluenza
viru
isol
patient
respiratori
syncyti
viru
rsv
clinic
signific
posit
ebv
pcr
bal
unknown
includ
analysi
posit
ebv
result
detect
bal
pcr
parainfluenza
rsv
isol
bal
viral
respiratori
shell
vial
cultur
common
radiograph
pattern
parainfluenza
rsv
influenza
diffus
ggo
occasion
area
nodular
consolid
composit
bal
parainfluenza
rsv
influenza
bal
identifi
bacterium
fungu
addit
viru
case
rsv
treat
ribavirin
fifteen
bal
specimen
concurr
pathogen
common
combin
bacterium
fungu
follow
fungu
viru
bacteria
viru
bal
specimen
isol
pathogen
total
patient
underw
bal
total
number
repeat
bal
number
repeat
bal
rang
repeat
bal
perform
within
day
none
show
new
pathogen
median
interv
repeat
bal
remain
day
rang
day
four
repeat
bal
show
persist
organ
isol
first
bal
despit
administr
appropri
antimicrobi
therapi
persist
organ
note
mrsa
pseudomona
aspergillu
identifi
bal
cultur
parainfluenza
vulner
popul
fob
bal
consid
safe
accur
complic
rate
fob
bal
sct
recipi
low
transbronchoscop
lung
biopsi
perform
addit
bal
complic
rate
high
safeti
profil
low
complic
rate
make
commonli
use
diagnost
tool
sct
recipi
undergo
infecti
pulmonari
major
limit
obtain
accept
sputum
sampl
includ
patient
effort
cooper
qualiti
sampl
colon
contamin
overal
low
yield
posit
sputum
cultur
infrequ
posit
impact
clinic
care
reason
routin
order
sputum
cultur
patient
pneumonia
studi
show
sputum
cultur
collect
yield
true
pathogen
correl
retriev
bal
find
support
notion
obtain
bal
specimen
critic
part
infecti
sct
recipi
provid
valuabl
microbiolog
inform
combin
infecti
noninfecti
diagnost
yield
bal
sct
recipi
reason
variabl
microbiolog
yield
bal
prior
studi
includ
differ
patient
popul
empir
antimicrobi
regimen
differ
among
health
care
institut
variou
test
protocol
methodolog
bal
sampl
studi
report
overal
microbiolog
yield
bal
specimen
obtain
sct
recipi
undergo
infecti
pulmonari
administr
prophylact
preemptiv
antimicrobi
therapi
common
sct
patient
empir
antimicrobi
therapi
associ
improv
clinic
howev
earli
aggress
use
empir
regimen
conceptu
thought
decreas
microbiolog
yield
bal
sampl
cohort
patient
true
pathogen
identifi
bal
treatment
antimicrobi
therapi
initi
least
hour
bal
collect
addit
cohort
bal
detect
mrsa
pseudomona
aspergillu
combin
take
appropri
therapi
target
specif
pathogen
therefor
receipt
concurr
antimicrobi
therapi
dissuad
oper
perform
bal
patient
popul
mrsa
pneumonia
associ
poor
outcom
frequent
necessit
empir
antibiot
therapi
recent
studi
report
neg
mrsa
pcr
ns
specimen
neg
predict
valu
mrsa
report
similar
find
wherein
mrsa
nss
perform
neg
bal
sputum
cultur
neg
case
neg
mrsa
patient
posit
mrsa
pcr
ns
also
mrsa
growth
bal
cultur
mrsa
pcr
ns
posit
predict
valu
neg
predict
valu
given
similar
find
present
studi
neg
mrsa
pcr
ns
may
use
antimicrobi
therapi
sct
recipi
immunocompet
patient
isol
aspergillu
sputum
bal
sampl
absenc
compat
clinic
sign
symptom
thought
repres
airway
contamin
colon
howev
immunocompromis
patient
aspergillu
emerg
import
caus
morbid
recoveri
aspergillu
respiratori
secret
sct
recipi
report
posit
predict
valu
high
isol
requir
treatment
report
observ
base
microbiolog
data
realiz
posit
studi
would
consid
signific
immunosuppress
cohort
proven
otherwis
studi
found
posit
bal
cultur
posit
bal
aspag
concord
observ
two
test
concord
seen
posit
bal
cultur
serum
aspag
lack
concord
among
variou
method
detect
aspergillu
inde
surpris
encourag
clinician
use
multipl
modal
identifi
presenc
aspergillu
speci
caus
pulmonari
infiltr
vulner
popul
institut
locat
desert
southwestern
unit
state
coccidioidomycosi
endem
coccidioid
ill
commonli
manifest
respiratori
ill
thu
evalu
perform
cocci
bal
pcr
sct
recipi
sinc
sct
recipi
routin
receiv
azol
prophylaxi
prevent
invas
candida
mold
infect
practic
also
like
reduc
incid
coccidioidomycosi
cohort
bal
sampl
isol
coccidioid
speci
concord
posit
bal
pcr
among
addit
cocci
bal
pcr
concord
posit
cocci
serolog
test
overal
patient
posit
cocci
serolog
test
among
concurr
posit
bal
pcr
immunosuppress
host
lower
rate
seroconvers
infect
fact
like
contribut
low
preval
posit
cocci
serolog
popul
therefor
multipl
modal
might
necessari
diagnos
coccidioidomycosi
sct
recipi
similar
aspergillu
infect
although
ebv
common
viru
detect
bal
clinic
signific
posit
bal
ebv
pcr
known
offer
meaning
clinic
inform
sct
recipi
sinc
elimin
bal
ebv
pcr
bal
ich
bundl
order
set
thu
consid
parainfluenza
common
real
viral
pathogen
isol
cohort
notabl
observ
bal
parainfluenza
isol
may
may
local
parainfluenza
outbreak
filmarray
respiratori
panel
farp
biofir
diagnost
inc
salt
lake
citi
ut
usa
assess
presenc
respiratori
virus
atyp
bacteri
pathogen
via
pcr
introduc
institut
end
studi
period
part
data
collect
therefor
unabl
comment
whether
np
farp
bal
farp
would
provid
addit
inform
cohort
azadeh
et
compar
yield
concurr
np
vs
bal
farp
institut
conclud
pathogen
identifi
np
farp
bal
farp
unlik
add
new
microbiolog
inform
convers
bal
farp
may
identifi
caus
respiratori
pathogen
perform
within
day
neg
np
swab
go
forward
would
interest
studi
util
np
vs
bal
farp
sct
popul
patient
underw
multipl
bal
although
sampl
size
small
observ
repeat
bal
within
day
provid
addit
microbiolog
inform
rather
reveal
persist
origin
pathogen
despit
appropri
therapi
seri
case
chest
ct
within
hour
fob
chest
ct
scan
may
sensit
chest
radiograph
ct
standard
diagnost
tool
initi
assess
invas
pulmonari
aspergillosi
opportunist
pulmonari
infect
sct
retrospect
studi
thu
inher
limit
assess
impact
bal
result
antimicrobi
therapi
ie
alter
initi
morbid
death
studi
design
analyz
microbiolog
yield
bal
specif
complic
rate
fob
collect
also
studi
result
may
generaliz
sct
patient
institut
region
knowledg
largest
retrospect
studi
date
look
microbiolog
yield
fob
bal
sct
recipi
abl
demonstr
sputum
cultur
unreli
detect
pulmonari
pathogen
popul
addit
obtain
bal
sampl
despit
patient
receiv
antimicrobi
therapi
least
hour
sampl
collect
continu
valuabl
diagnost
test
consid
immunosuppress
cohort
bal
essenti
diagnost
tool
sct
recipi
undergo
infecti
pulmonari
studi
show
overal
bal
microbiolog
yield
despit
group
receiv
empir
antimicrobi
therapi
bal
collect
although
initi
bal
sampl
provid
critic
microbiolog
inform
repeat
bal
within
day
may
addit
diagnost
yield
kk
research
conceptdesign
data
collect
analysi
interpret
draft
articl
critic
revis
articl
approv
articl
ck
data
collect
analysi
critic
revis
articl
approv
articl
kb
data
collect
critic
revis
articl
approv
articl
tg
js
lw
data
analysi
interpret
critic
revis
articl
approv
articl
hrv
research
conceptdesign
data
analysi
interpret
critic
revis
articl
approv
articl
author
conflict
interest
declar
